PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A

Update Il y a 4 ans
Reference: NCT02492984

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

An open-label, single-arm, post- authorization pragmatic clinical trial on the safety and efficacy of Xyntha (Moroctocog-alfa (AF-CC), Recombinant FVIII) in subjects with hemophilia A in usual care settings in China for approximately 6 months or or approximately 50 exposure days whichever occurs first


Inclusion criteria

  • Hemophilia A

Links